IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency

Scand J Immunol. 1997 Feb;45(2):203-12. doi: 10.1046/j.1365-3083.1997.d01-381.x.

Abstract

In the present study the phenotype and function of lymphocytes from patients with common variable immunodeficiency (CVI) were studied. Five out of 12 patients had abnormally low proportion of CD4+ T cells, but PBMC of these patients were capable of proliferating in response to polyclonal T-cell mitogens or PPD antigen. The phenotype of patients' B cells, as determined by expression of CD10, CD19 and CD34, was comparable to that of healthy controls. IL-4 and anti-CD40 MoAbs induced moderate B-cell differentiation in PBMC derived from patients with CVI, but the frequencies of Ig-secreting cells were generally at levels spontaneously observed in healthy controls. IL-10 was completely ineffective in inducing IgG-secreting cells in cultures of PBMC derived from patients with CVI even in the presence of anti-CD40 MoAbs, whereas high frequencies of Ig-secreting cells were induced under similar condition in cultures of PBMC derived from healthy controls. Importantly, when IL-4 was added to cultures stimulated with anti-CD40 MoAbs and IL-10, a very strong synergistic effect on the numbers of Ig-secreting cells and the levels of Ig secretion was observed in PBMC from both patients and controls. Moreover, the frequencies of Ig-secreting cells after activation with anti-CD40 MoAbs, IL-4 plus IL-10 in PBMC from some patients were comparable to those observed in PBMC from healthy controls. Taken together, these results indicate that B cells from patients with CVI have impaired capacity to differentiate into Ig-secreting cells in response to IL-10 and anti-CD40 MoAbs, and that this unresponsiveness can be restored by exogenous IL-4 in a proportion of the patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal / pharmacology*
  • Antigens, CD19 / analysis
  • Antigens, CD19 / immunology
  • Antigens, CD34 / analysis
  • Antigens, CD34 / immunology
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / metabolism*
  • Bacterial Proteins / pharmacology
  • CD3 Complex / analysis
  • CD3 Complex / immunology
  • CD4 Lymphocyte Count
  • CD4-CD8 Ratio
  • CD40 Antigens / immunology*
  • CD8 Antigens / analysis
  • CD8 Antigens / immunology
  • Cells, Cultured
  • Child
  • Common Variable Immunodeficiency / immunology*
  • Concanavalin A / pharmacology
  • Drug Synergism
  • Female
  • Flow Cytometry
  • HLA-DR Antigens / analysis
  • HLA-DR Antigens / immunology
  • Humans
  • Immunoglobulins / metabolism
  • Interleukin-10 / pharmacology*
  • Interleukin-13 / pharmacology
  • Interleukin-2 / pharmacology
  • Interleukin-4 / pharmacology*
  • Leukocyte Common Antigens / analysis
  • Leukocyte Common Antigens / immunology
  • Leukocytes, Mononuclear / drug effects*
  • Lymphocyte Activation*
  • Male
  • Middle Aged
  • Phytohemagglutinins / pharmacology
  • Pokeweed Mitogens / pharmacology
  • Receptors, Interleukin-2 / analysis
  • Receptors, Interleukin-2 / immunology
  • Recombinant Proteins / pharmacology
  • Tuberculin / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antigens, CD19
  • Antigens, CD34
  • Bacterial Proteins
  • CD3 Complex
  • CD40 Antigens
  • CD8 Antigens
  • HLA-DR Antigens
  • Immunoglobulins
  • Interleukin-13
  • Interleukin-2
  • Phytohemagglutinins
  • Pokeweed Mitogens
  • Receptors, Interleukin-2
  • Recombinant Proteins
  • Tuberculin
  • anticoagulant protein, Streptomyces cinnamoneus
  • phytohemagglutinin-M
  • Concanavalin A
  • Interleukin-10
  • Interleukin-4
  • Leukocyte Common Antigens